Receptor-Mediated Drug Delivery Systems Targeting to Glioma

Nanomaterials

Shanshan Wang²  Ying Meng²  Chengyi Li²  Min Qian²  Rongqin Huang¹  Subramanian Tamil Selvan²  Wolfgang J. Parak² 

[1] Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China

关键词: glioma;    blood-brain barrier (BBB);    receptor-mediated;    single ligand-modified targeting systems;    dual ligand-modified targeting systems;   

DOI  :  10.3390/nano6010003

来源: mdpi

【 摘 要 】

Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.